Bianchi 34-marker miRNA Signature for Lung Cancer
This signature was developed based on the detection of 34 microRNAs (miRNAs) from serum that could identify patients with early stage non-small cell lung carcinomas (NSCLCs) in a population of asymptomatic high-risk individuals with 80% accuracy. The signature could assign disease probability accurately either in asymptomatic or symptomatic patients, is able to distinguish between benign and malignant lesions, and to capture the onset of the malignant disease in individual patients over time.
No member markers defined for this panel.
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
A diagnostic signature of 34 serum miRNAs was identified. The signature can identify patients with early stage NSCLC with 80% overall accuracy. In addition, the signature can distinguish between benign lung nodules (which are a frequent occurrence in at-risk individuals) and frank NSCLCs. Finally, the signature can capture the time of disease onset in individual patients over time.
No associated resources found.